AGM
PMVP icon

Alpine Global Management’s PMV Pharmaceuticals PMVP Stock Holding History

Alpine Global Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,701
Closed -$415K – 284
2020
Q3 		$415K Buy
+11,701
New +$431K 0.09% 121

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Global Management's PMVP Position: Q4 2020 in Review

Alpine Global Management sold out of PMV Pharmaceuticals (PMVP) in Q4 2020, closing a stake of 11,701 shares — an estimated $415K sold.

Alpine Global Management first reported a position in PMVP in Q3 2020 and held it in 1 quarter. The position peaked at $415K in Q3 2020. 73 funds tracked by Wall St. Rank hold PMVP as of Q4 2020.

  • Alpine Global Management reported no remaining PMV Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Alpine Global Management sold 11,701 PMV Pharmaceuticals shares in Q4 2020, an estimated $415K.
  • Alpine Global Management first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Alpine Global Management's PMV Pharmaceuticals position peaked at $415K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2020.

Based on Alpine Global Management's 13F filing for Q4 2020, filed 12 Feb 2021.